
Iterum Therapeutics plc Ordinary Share
ITRM
ITRM: Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
moreShow ITRM Financials
Recent trades of ITRM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ITRM's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Combinations of beta-lactam compounds and probenecid and uses thereof Oct. 25, 2022
Federal grants, loans, and purchases
Followers on ITRM's company Twitter account
Number of mentions of ITRM in WallStreetBets Daily Discussion
Recent insights relating to ITRM
Recent picks made for ITRM stock on CNBC
ETFs with the largest estimated holdings in ITRM
Flights by private jets registered to ITRM